Žiadne pripojenie na internet — zobrazuje sa uložená verzia stránky.

Cellectis SA

USUSD
← Do Screenera

Cellectis SA (US:CMVLF) — Biotechnology: Pharmaceutical Preparations. Počet búrz, na ktorých sa obchodujú akcie spoločnosti: 3. Na tejto stránke — cena a graf, dividendy, najväčší akcionári a história počtu akcií.

O Spoločnosti

Web
cellectis.com
Vzťahy s Investormi
cellectis.com/en/investors/governance/
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sídlo
France, France
Generálny Riaditeľ
Andre Choulika
Zamestnanci
224
Založená
1999
Akcie v Obehu
72.72 mil.
Voľne Obchodovateľné Akcie
48.58 mil.
Trhová Kapitalizácia
148.06 mil. USD
Insideri
0%
Inštitucionálni Investori
15.36%
Odvetvie (SIC)
Biological Products, (No Diagnostic Substances)
Právna Forma
QVPB
ISIN
FR0010425595
LEI
5493000KKX5VQ37Q2W83
FCF
−41.8 mil. USD
Dlh
?
Zisky a FCF — za 12 mesiacov do roku 31.12.2025 (najnovšia správa spoločnosti).
NAV
1.04 USD · P/NAV 3.32
Balance sheet date31.12.2025
Assets325 mil. USD
− Liabilities249 mil. USD
= NAV (vlastný kapitál akcionárov spoločnosti)75.9 mil. USD
− Intangible assets535 tis. USD
= Tangible NAV75.4 mil. USD
Akcie72 718 974
NAV per share1.04 USD
Hmatateľný NAV na Akciu1.04 USD
Share price (CMVLF)3.4700 USD
P/NAV3.32
NAV history
Balance sheet dateNAVNAV per share
31.12.202575.9 mil. USD1.04 USD
31.12.2024131 mil. USD1.80 USD
31.12.202384.7 mil. USD1.18 USD
30.09.202376.1 mil. USD1.05 USD
30.06.202396.6 mil. USD1.33 USD
31.12.2022118 mil. USD1.29 USD
31.12.2021221 mil. USD4.87 USD
31.12.2020284 mil. USD6.63 USD
Popis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

reklama

Burzy a Tickery

BurzaTickerMenaCenaTyp
US USA StocksCMVLF OTCUSD3.47 +12.66%kmeňové akcie
LSE London Stock Exchange0WA2 IOBEUR2.65 +0.00%kmeňové akcie
PA Euronext ParisALCLS hlavnéEUR1.043 -2.71%kmeňové akcie

Cena za 3 Mesiace

US:CMVLF sa v posledných 3 mesiacoch neobchodoval — graf zobrazuje PA:ALCLS
deň rastu deň poklesuPrejdite myšou / ťuknite na deň — otváracia, záverečná, najvyššia a najnižšia cena

Najväčší Držitelia

DržiteľPodielAkcieDátum Správy
B Group, Inc.4.55%3.28 mil.2026-06-30
Long Focus Capital Manag…3.8%2.74 mil.2026-06-30
UBS AM, a distinct busin…3.67%2.64 mil.2026-06-30
iShares Trust-iShares Bi…0.33%235 6962026-08-31
Nomura Asset Management…0.31%226 8752026-06-30
Delaware Group Equity Fu…0.31%226 8752026-06-30
Blackrock Inc.0.31%225 4442026-06-30
Morgan Stanley0.12%85 4552026-06-30
LPL Financial LLC0.12%84 4152026-06-30
Susquehanna Internationa…0.07%50 4532026-06-30
BNP Paribas Financial Ma…0.06%40 1002026-06-30
UBS Group AG0.05%33 9262026-06-30
Fidelity Concord Street…0%1 9492026-07-31